Description

IVERVID 12 MG

Indications

IVERVID 12 MG is a medication primarily indicated for the treatment of various parasitic infections, particularly those caused by helminths and certain protozoa. It is commonly used in the management of conditions such as strongyloidiasis, ascariasis, and other helminthic infections. IVERVID is also utilized in the treatment of onchocerciasis, commonly known as river blindness, and has shown efficacy in managing conditions related to filarial infections.

Mechanism of Action

The active ingredient in IVERVID is Ivermectin, which works by binding to specific ion channels in the nerve and muscle cells of parasites. This binding leads to an increase in the permeability of the cell membranes to chloride ions, resulting in paralysis and death of the parasites. Ivermectin’s action is particularly effective against adult worms and larvae, disrupting their ability to reproduce and survive within the host. Additionally, it has a low affinity for mammalian channels, which contributes to its safety profile in human use.

Pharmacological Properties

IVERVID 12 MG exhibits a broad spectrum of activity against various parasites. It is well-absorbed after oral administration, with peak plasma concentrations typically reached within 4 hours. The drug has a half-life of approximately 12 hours, allowing for once-daily dosing in many cases. Ivermectin is metabolized in the liver and excreted primarily through the feces, with a minor portion eliminated in the urine. The pharmacokinetics of Ivermectin can vary based on factors such as age, weight, and liver function, necessitating careful consideration when prescribing this medication.

Contraindications

IVERVID should not be used in individuals with a known hypersensitivity to Ivermectin or any of its components. It is also contraindicated in patients with severe liver impairment or those who are pregnant, particularly during the first trimester, due to potential risks to the fetus. Caution is advised in patients with a history of neurological disorders, as the safety of Ivermectin in such populations has not been fully established.

Side Effects

Common side effects associated with IVERVID 12 MG include dizziness, nausea, diarrhea, and abdominal pain. Some patients may experience skin rashes or itching as a result of the drug’s action on parasites. In rare cases, more severe side effects may occur, such as hypotension, seizures, or severe allergic reactions. It is important for patients to report any unusual or severe symptoms to their healthcare provider promptly.

Dosage and Administration

The recommended dosage of IVERVID 12 MG varies depending on the specific infection being treated. For strongyloidiasis, a single dose of 200 micrograms per kilogram of body weight is typically administered. For other helminthic infections, the dosage may range from a single dose to a multi-day regimen, depending on the severity and type of infection. It is essential to follow the prescribing physician’s instructions regarding dosage and duration of treatment to ensure optimal efficacy and minimize the risk of resistance development.

Interactions

IVERVID may interact with other medications, which can alter its effectiveness or increase the risk of adverse effects. Caution should be exercised when co-administering Ivermectin with drugs that are known to affect liver enzymes, such as certain anticonvulsants and anti-HIV medications. Additionally, the use of Ivermectin alongside other antiparasitic agents may enhance the risk of toxicity. It is crucial for patients to inform their healthcare provider of all medications, supplements, and herbal products they are currently taking to avoid potential interactions.

Precautions

Before starting treatment with IVERVID, patients should undergo a thorough medical evaluation, particularly if they have a history of liver disease, neurological disorders, or are taking other medications. Regular monitoring may be necessary to assess the drug’s efficacy and to check for any adverse effects. Patients should also be advised to avoid self-medication and to adhere strictly to the prescribed dosage to minimize the risk of complications.

Clinical Studies

Numerous clinical studies have demonstrated the effectiveness of IVERVID 12 MG in treating various parasitic infections. In randomized controlled trials, Ivermectin has shown significant efficacy in reducing parasite load and improving clinical outcomes in patients with strongyloidiasis and onchocerciasis. Long-term follow-up studies have indicated that Ivermectin can effectively reduce the incidence of disease transmission in endemic areas, contributing to public health efforts in controlling parasitic infections. These findings support the continued use of Ivermectin as a first-line treatment option for specific parasitic diseases.

Conclusion

IVERVID 12 MG is a valuable therapeutic option for the treatment of various parasitic infections. Its effective mechanism of action, favorable pharmacokinetic profile, and established safety record make it a preferred choice among healthcare providers. However, careful consideration of contraindications, potential side effects, and drug interactions is essential to ensure patient safety and treatment success. Ongoing research continues to explore the broader applications of Ivermectin in parasitic disease management, further solidifying its role in global health initiatives.